Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating Daclizumab High-Yield Process in Multiple Sclerosis


Monday, 16 Jun 2014 07:30am EDT 

Biogen Idec and AbbVie Inc:Says positive top-line results from Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular interferon beta-1a (IFN β-1a).Results showed that DAC HYP was superior on the study's primary endpoint, demonstrating a statistically 45 pct reduction in annualized relapse rate (ARR) compared to IFN β-1a. 

Company Quote

52.37
-1.38 -2.57%
31 Jul 2014